Anti‐fibrotic effects of different sources of MSC in bleomycin‐induced lung fibrosis in C57BL6 male mice

IPF is a fatal and debilitating lung disorder increasing in incidence worldwide. To date, two approved treatments only slow disease progression, have multiple side effects and do not provide a cure. MSC have promising therapeutic potential as a cell‐based therapy for many lung disorders based on the anti‐fibrotic properties of the MSC.

[1]  Yu-Show Fu,et al.  Reversal of bleomycin-induced rat pulmonary fibrosis by a xenograft of human umbilical mesenchymal stem cells from Wharton's jelly , 2019, Theranostics.

[2]  A. Thakor,et al.  Mesenchymal Stromal Cell Homing: Mechanisms and Strategies for Improvement , 2019, iScience.

[3]  Yuanlin Song,et al.  Better therapeutic potential of bone marrow-derived mesenchymal stem cells compared with chorionic villi-derived mesenchymal stem cells in airway injury model. , 2019, Regenerative medicine.

[4]  D. Bouros,et al.  Existing and emerging treatments for idiopathic pulmonary fibrosis , 2019, Expert review of respiratory medicine.

[5]  Jie Hao,et al.  Comparative analysis of mesenchymal stem cells derived from amniotic membrane, umbilical cord, and chorionic plate under serum-free condition , 2019, Stem Cell Research & Therapy.

[6]  T. Suda,et al.  The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype , 2018, European Respiratory Review.

[7]  Y. Yang.  Aging of mesenchymal stem cells: Implication in regenerative medicine , 2018, Regenerative therapy.

[8]  N. Kaminski,et al.  Gene correlation network analysis to identify regulatory factors in idiopathic pulmonary fibrosis , 2018, Thorax.

[9]  M. Tomic-Canic,et al.  Mesenchymal stromal cells prevent bleomycin‐induced lung and skin fibrosis in aged mice and restore wound healing , 2018, Journal of cellular physiology.

[10]  T. Gille,et al.  Intermittent Hypoxia Increases the Severity of Bleomycin-Induced Lung Injury in Mice , 2018, Oxidative medicine and cellular longevity.

[11]  T. Brümmendorf,et al.  Comprehensive characterization of chorionic villi-derived mesenchymal stromal cells from human placenta , 2018, Stem Cell Research & Therapy.

[12]  R. Hubbard,et al.  Timing of onset of symptoms in people with idiopathic pulmonary fibrosis , 2017, Thorax.

[13]  P. Giannoudis,et al.  Age-related Changes in Bone Marrow Mesenchymal Stromal Cells , 2017, Cell transplantation.

[14]  V. Aidinis,et al.  Exploring Animal Models That Resemble Idiopathic Pulmonary Fibrosis , 2017, Front. Med..

[15]  Mark G. Jones,et al.  Idiopathic pulmonary fibrosis , 2017, The Lancet.

[16]  J. Davies,et al.  Concise Review: Wharton's Jelly: The Rich, but Enigmatic, Source of Mesenchymal Stromal Cells , 2017, Stem cells translational medicine.

[17]  R. Chambers,et al.  An Official American Thoracic Society Workshop Report: Use of Animal Models for the Preclinical Assessment of Potential Therapies for Pulmonary Fibrosis , 2017, American journal of respiratory cell and molecular biology.

[18]  G. Salton,et al.  Comparison of human mesenchymal stromal cells from four neonatal tissues: Amniotic membrane, chorionic membrane, placental decidua and umbilical cord. , 2017, Cytotherapy.

[19]  G. Rosen,et al.  Allogeneic Human Mesenchymal Stem Cells in Patients With Idiopathic Pulmonary Fibrosis via Intravenous Delivery (AETHER): A Phase I Safety Clinical Trial , 2017, Chest.

[20]  M. Pittenger,et al.  Concise Review: MSC‐Derived Exosomes for Cell‐Free Therapy , 2017, Stem cells.

[21]  H. Collard.  Improving Survival in Idiopathic Pulmonary Fibrosis: The Race Has Just Begun. , 2017, Chest.

[22]  A. Shafiee,et al.  Avoidance of Maternal Cell Contamination and Overgrowth in Isolating Fetal Chorionic Villi Mesenchymal Stem Cells from Human Term Placenta , 2017, Stem cells translational medicine.

[23]  M. Strek,et al.  Therapeutic Approach to Adult Fibrotic Lung Diseases , 2016, Chest.

[24]  N. Henderson,et al.  αv integrins: key regulators of tissue fibrosis , 2016, Cell and Tissue Research.

[25]  H. Collard,et al.  Incidence and prevalence of idiopathic pulmonary fibrosis in US adults 18–64 years old , 2016, European Respiratory Journal.

[26]  Rachel C Chambers,et al.  Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF , 2016, Thorax.

[27]  O. Hammam,et al.  Wharton’s jelly-derived mesenchymal stem cells combined with praziquantel as a potential therapy for Schistosoma mansoni-induced liver fibrosis , 2016, Scientific Reports.

[28]  M. Ashraf,et al.  Abrogation of Age‐Induced MicroRNA‐195 Rejuvenates the Senescent Mesenchymal Stem Cells by Reactivating Telomerase , 2016, Stem cells.

[29]  M. Glassberg,et al.  Therapeutic benefits of young, but not old, adipose-derived mesenchymal stem cells in a chronic mouse model of bleomycin-induced pulmonary fibrosis. , 2015, Translational research : the journal of laboratory and clinical medicine.

[30]  K. Thangaraj,et al.  Propagation of pure fetal and maternal mesenchymal stromal cells from terminal chorionic villi of human term placenta , 2015, Scientific Reports.

[31]  K. Pandit,et al.  MicroRNA regulatory networks in idiopathic pulmonary fibrosis. , 2015, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[32]  C. Wells,et al.  High Incidence of Contaminating Maternal Cell Overgrowth in Human Placental Mesenchymal Stem/Stromal Cell Cultures: A Systematic Review , 2014, Stem cells translational medicine.

[33]  Wei Cao,et al.  Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications , 2014, Nature Immunology.

[34]  Guoying Yu,et al.  MicroRNA mimicry blocks pulmonary fibrosis , 2014, EMBO molecular medicine.

[35]  R. Sussman,et al.  A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. , 2014, The New England journal of medicine.

[36]  N. Kaminski,et al.  Aging mesenchymal stem cells fail to protect because of impaired migration and antiinflammatory response. , 2014, American journal of respiratory and critical care medicine.

[37]  P. Blit,et al.  Effect of Human Wharton's Jelly Mesenchymal Stem Cell Paracrine Signaling on Keloid Fibroblasts , 2014, Stem cells translational medicine.

[38]  P. Blit,et al.  Human Wharton’s jelly mesenchymal stem cells promote skin wound healing through paracrine signaling , 2014, Stem Cell Research & Therapy.

[39]  Y. Moodley,et al.  Anti-Inflammatory Effects of Adult Stem Cells in Sustained Lung Injury: A Comparative Study , 2013, PloS one.

[40]  T. Du,et al.  Human Wharton’s jelly-derived mesenchymal stromal cells reduce renal fibrosis through induction of native and foreign hepatocyte growth factor synthesis in injured tubular epithelial cells , 2013, Stem Cell Research & Therapy.

[41]  F. Luo,et al.  MiR‐29 mediates TGFβ1‐induced extracellular matrix synthesis through activation of PI3K‐AKT pathway in human lung fibroblasts , 2013, Journal of cellular biochemistry.

[42]  Faizal Z. Asumda.  Age-associated changes in the ecological niche: implications for mesenchymal stem cell aging , 2013, Stem Cell Research & Therapy.

[43]  V. Cottin,et al.  Neglected evidence in idiopathic pulmonary fibrosis: from history to earlier diagnosis , 2013, European Respiratory Journal.

[44]  H. Papadaki,et al.  Mesenchymal stem cells derived from Wharton's Jelly of the umbilical cord: biological properties and emerging clinical applications. , 2013, Current stem cell research & therapy.

[45]  T. Luedde,et al.  miR-199a-5p Is Upregulated during Fibrogenic Response to Tissue Injury and Mediates TGFbeta-Induced Lung Fibroblast Activation by Targeting Caveolin-1 , 2013, PLoS genetics.

[46]  Athol U. Wells,et al.  Idiopathic pulmonary fibrosis , 2012, Nature Reviews Disease Primers.

[47]  J. Qian,et al.  miR-29 is a major regulator of genes associated with pulmonary fibrosis. , 2011, American journal of respiratory cell and molecular biology.

[48]  V. Clifton.  Review: Sex and the human placenta: mediating differential strategies of fetal growth and survival. , 2010, Placenta.

[49]  A. Trounson,et al.  Human umbilical cord mesenchymal stem cells reduce fibrosis of bleomycin-induced lung injury. , 2009, The American journal of pathology.

[50]  Thomas D. Schmittgen,et al.  Analyzing real-time PCR data by the comparative CT method , 2008, Nature Protocols.

[51]  Lindolfo da Silva Meirelles,et al.  Mesenchymal stem cells reside in virtually all post-natal organs and tissues , 2006, Journal of Cell Science.

[52]  H. Haider,et al.  Bone marrow stem cell transplantation for cardiac repair. , 2005, American journal of physiology. Heart and circulatory physiology.

[53]  W. H. McLean,et al.  Isolation, culture and characterisation of fibroblast-like cells derived from the Wharton's jelly portion of human umbilical cord. , 1991, Biochemical Society transactions.

[54]  J M Simpson,et al.  Simple method of estimating severity of pulmonary fibrosis on a numerical scale. , 1988, Journal of clinical pathology.

[55]  S. Kar,et al.  Therapeutic potential of Umbilical Cord Derived Mesenchymal Stem Cells in Bleomycin-Induced Idiopathic Pulmonary Fibrosis in BALB/c Mice , 2017 .

[56]  C. Borlongan,et al.  Discarded Wharton jelly of the human umbilical cord: a viable source for mesenchymal stromal cells. , 2015, Cytotherapy.

[57]  Takeshi Johkoh,et al.  American Thoracic Society Documents An Official ATS / ERS / JRS / ALAT Statement : Idiopathic Pulmonary Fibrosis : Evidence-based Guidelines for Diagnosis and Management , 2011 .